Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of California, San Francisco
Gilead Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Centre Oscar Lambret
University of Washington
Astellas Pharma Inc
Hoffmann-La Roche
University of Florida
Nanjing Leads Biolabs Co.,Ltd
Merck Sharp & Dohme LLC
Stichting Hemato-Oncologie voor Volwassenen Nederland
Medical College of Wisconsin
Hospital Universitario Dr. Jose E. Gonzalez
Alliance for Clinical Trials in Oncology
Merck Sharp & Dohme LLC
University of California, San Francisco
Eastern Cooperative Oncology Group
Hoffmann-La Roche
University of Arizona
BioNTech SE
Janssen Research & Development, LLC
Thomas Jefferson University
Corcept Therapeutics
M.D. Anderson Cancer Center
Intergroupe Francophone de Cancerologie Thoracique
AstraZeneca
Gruppo Oncologico Italiano di Ricerca Clinica
First Affiliated Hospital of Zhejiang University
AstraZeneca
Ohio State University Comprehensive Cancer Center
Canadian Cancer Trials Group
Dana-Farber Cancer Institute
Shanghai Guangsheng Biopharmaceutical Co., Ltd
Canadian Cancer Trials Group
AstraZeneca
Wake Forest University Health Sciences
Canadian Cancer Trials Group
TJ Biopharma Co., Ltd.
UNC Lineberger Comprehensive Cancer Center